In the present invention which is the result of intensive studies, the inventors have discovered the possibility to speculate on the potential agonism/antagonism of synthetic DC-SIGN inhibitors or their intrinsic activity with a method, that ensures culturing of dendritic cells (DCs) in the presence or absence of synthetic DC-SIGN inhibitors with simultaneous activation with or without TLR agonists. The proposed invention therefore firstly represents a method to determine the intrinsic activity of synthetic inhibitors of DC-SIGN based on the modulation of DCs' cytokine profile. The proposed invention also ensures the use of this method to determine the intrinsic activity of synthetic DC-SIGN inhibirtors. At the same time, the proposed invention ensures the use of this method to evaluate the therapeutiv potential of synthetiv DC-SIGN inhibitors as anti-microbial agents.
F.33 Slovenian patent
COBISS.SI-ID: 3212145In our work a test system for the determination of potential antagonists of the receptor DC-SIGN in vitro was developed and optimized. Effectiveness of potential ligands which are focused on the inhibition of DC-SIGN responsible for transmission of HIV infection was evaluated. Efficiency of the system was evaluated with flow cytometry. The test system will be used as a routine test for the determination of inhibitory constants of novel synthetic DC-SIGN antagonists. The research will be used as a tool for development of potential anti-infective compounds.
D.10 Educational activities
COBISS.SI-ID: 3511409In this work we have demonstrated the synergy between the cytokines IFN-g and IL-10 in inducing a tolerogenic phenotype and function in human dendritic cells.
D.10 Educational activities
COBISS.SI-ID: 7900537The main purpose of our study was the establishment of a test system for determining of potential agonism/antagonism of DC-SIGN inhibitors. For development of novel DC-SIGN ligands/inhibitors we need information regarding their potential capacity to induce DC-SIGN-mediated signaling and therefore influence the immune response mediated by DCs. In this way we can better answer questions arising during design and development of novel DC-SIGN ligands and evaluate their therapeutic potential.
D.10 Educational activities
COBISS.SI-ID: 6852473[London] : Biomed Central.
C.04 Editorial board of an international magazine